Search Results for “diagnostic” – Page 45 – media

Roche Cuts Pipeline as COVID, Currency Headwinds Impact Q3 Results

Pictured: Roche tower in Switzerland/iStock, olli0815 Roche is eliminating four clinical programs amid drooping sales brought about by a sharp decline in demand for COVID-19 products and a strong Swiss franc, the pharma group announced Thursday morning in its third-quarter earnings results. According to a development pipeline document released alongside the quarterly report, Roche will end a Phase I solid tumor trial for its investigational CEA/CD3 bispecific antibody cibisatamab. The company will also stop Phase II trials of its antipsychotic drug candidate ralmitaront in schizophrenia and the developmental cannabinoid receptor agonist vicasinabin in diabetic retinopathy. Roche discontinued the mid-stage study of ralmitaront after it failed a Phase II trial in May 2023, unable to elicit significant improvements on negative symptoms in a preliminary analysis. The vicasinabin and cibisatamab programs were likewise scrapped following underwhelming reviews of their efficacy in their respective studies. However, in a media call Thursday morning, a Roche spokesperson said that these two ...
- Source: By Tristan Manalac
- 143
- October 31, 2023
Amazon Starts Delivering Medications via Drone

Amazon Pharmacy is working to speed up prescription medication delivery in College Station, Texas, through its free drone delivery service, the company announced Wednesday. With drones, Amazon said prescriptions can be delivered within 60 minutes. Customers in College Station can sign up for the drone delivery service by scheduling a free yard consultation, in which a local yard survey specialist will come to customers’ homes and examine their yards. If the specialist determines that the yard is suitable, then Amazon will provide a marker where the drone can deliver packages. Then when eligible customers order their medications, they can select drone delivery at checkout. The service is available for more than 500 medications that treat common conditions, such as flu, asthma and pneumonia. These medications include Levofloxacin, Bactrim, Atorvastatin and Levothyroxine. For many of these conditions, swift access to treatment is vital, but that doesn’t always happen, said Dr. Vin ...
- Source: drugdu
- 176
- October 20, 2023
Thermo Fisher Adds Proteomics to Its Portfolio Through $3.1B Olink Acquisition

Drug discovery increasingly requires sophisticated analysis of proteins, and Thermo Fisher Scientific is building up its capabilities to support such research with the $3.1 billion acquisition of Olink, a company whose technologies and services are used in laboratories around the world. According to deal terms announced Tuesday, Thermo Fisher, based in Waltham, Massachusetts, will pay $26 cash for each American depositary share of Olink. That price represents a premium of about 74% to the Uppsala, Sweden-based company’s closing stock price on Monday. When Olink made its Nasdaq debut in 2021, it priced shares at $20 apiece. Olink is a player in the field of proteomics, the analysis of proteins. But the company does not discover or develop new drugs. Rather, it provides tools and services for the scientists who do that research at biopharmaceutical companies and universities. The company sells kits that drug researchers can use to analyze proteins in ...
- Source: drugdu
- 234
- October 19, 2023
CHMP recommends European authorisation for seven new drugs

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended seven new drugs for authorisation. The drugs include Pfizer’s Elrexfio for the treatment of multiple myeloma and Astellas Pharma’s Veozah for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Elrexfio (elranatamab) is a subcutaneously administered bispecific B-cell maturation antigen-directed CD3 T-cell engager. The US Food and Drug Administration (FDA) granted accelerated approval for Elrexfio in August for patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. According to GlobalData, sales for Elrexfio are expected to reach $536m by 2029. One of its competitors in the market is Talvey (talquetamab-tgvs), marketed by Janssen, which was approved as a fifth-line treatment for relapsed/refractory multiple myeloma in August. Talvey is forecasted to generate $1.9bn in sales by 2029. Astellas Pharma’s Veozah ...
- Source: drugdu
- 112
- October 19, 2023
Quality of ultrasound scans of the liver and kidneys found to be lower in obese patients

Ultrasound of the abdominal organs is a central diagnostic tool and is recommended as the first-line approach for many medical conditions. Compared with other imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI), ultrasound is readily available, avoids unnecessary radiation exposure and can be used in almost every case. However, the accuracy of this method is usually limited in obese individuals because the imaging quality of anatomical structures is impaired. To date, the degree of obesity at which ultrasound diagnostics are no longer sufficiently precise has not been sufficiently researched. In a recent clinical study at the University of Leipzig Medical Center, researchers found that the quality of ultrasound scans of the liver and kidneys was significantly lower in obese patients. Professor Thomas Karlas, head of the study and corresponding author of the current publication, said, “The results showed that as the body mass index of the ...
- Source: drugdu
- 164
- October 18, 2023
GE HealthCare launches AI-enhanced point-of-care ultrasound

BY SEAN WHOOLEY Caption Guidance on the Venue Go system in use. [Image courtesy of GE HealthCare] GE HealthCare (Nasdaq: GEHC)+ announced today that it launched its Venue point-of-care ultrasound systems with AI-driven Caption Guidance. Chicago-based GE HealthCare says the Venue family is the first of its ultrasound guidance to include Caption Guidance. The company added the AI-driven imaging guidance to its arsenal when it acquired Caption Health earlier this year. Caption Guidance, an optional add-on, offers new capabilities at the point of care with diagnostic-quality cardiac images. It supports clinicians in a wide range of clinical settings, like emergency departments, critical care wards and anesthesiology. GE HealthCare says the Caption Guidance technology offers clinicians step-by-step instructions to acquire ultrasound for cardiac assessments. It helps providers — even those who aren’t ultrasound experts — by addressing training and skill barriers to ultrasound usage. This, in turn, expands ultrasound access. According ...
- Source: drugdu
- 156
- October 9, 2023
Ariceum doses first patient with satoreotide

by John Pinching The treatment targets extensive stage small cell lung cancer and aims to boost therapeutic impact Ariceum Therapeutics, a company developing products for the treatment of specific cancers, has announced that the first patient has been dosed with its satoreotide therapy. The treatment targets extensive stage small cell lung cancer (ES-SCLC), while the research is taking place at the Murdoch University Health Center in Australia. Ariceum’s broader open label phase 1b trial will analyse the tolerability and safety of the ‘theranostic pair’ of somatostatin receptor antagonists, ga-satoreotide trizoxetan and lu-satoreotide tetraxetan, among patients with ES-SCLC. The central aim of the research is to establish a recommended phase 2 dose and schedule in due course. ‘Theranostics’ is the system of incorporating two paired drugs: the first, a diagnostic agent to identify cells that exhibit a particular biomarker, and the second, a therapeutic drug which subsequently acts on those cells. ...
- Source: drugdu
- 206
- October 3, 2023
Medtronic in exclusive talks for $7B sale of units to private equity

Dive Brief The private equity firm Carlyle Group is leading the race to buy Medtronic’s connected patient monitoring and respiratory care operations, according to Reuters. Medtronic outlined plans to spin off the units almost one year ago. At the time, the company proposed creating a new connected care company, but the move reportedly led to interest from potential buyers including Siemens Healthineers and GE HealthCare. Now, with Medtronic nearing the end of its targeted window for completing a transaction, Reuters has reported that Carlyle has entered into exclusive negotiations to buy a majority stake in the two businesses at a valuation of more than $7 billion. Dive Insight Patient monitoring and respiratory interventions, part of Medtronic’s Medical Surgical portfolio, are among the slower-growing parts of the company. While neither business has the type of growth profile that Medtronic is targeting, they could be attractive to another company. According to Reuters, ...
- Source: https://www.medtechdive.com/news/medtronic--7b-deal-private-equity-carlyle-group/695282/
- 225
- October 3, 2023
Genentech, PeptiDream Ink Potential $1B Radiopharma Deal

By Kate Goodwin Pictured: Businessmen shaking hands/iStock, Tippapatt Japanese biopharma PeptiDream on Wednesday announced yet another licensing agreement with Roche’s Genentech, this time worth up to $1 billion. The latest deal builds on previous partnerships between the two companies starting in December 2015 with licensing in 2016 and an expansion deal in 2018. PeptiDream will receive $40 million upfront for R&D of its macrocyclic peptide-radioisotope drug conjugates. Going forward, another $1 billion is on the line in milestones plus tiered royalties of product sales to markets outside of Japan. PeptiDream will oversee preclinical activities to develop a peptide-RI drug conjugate and retain rights in Japan for any products developed. While a particular target was not disclosed, PeptiDream CEO Patrick Reid said in a statement that the company hopes to “bring innovative first-in-class peptide radiopharmaceuticals to patients worldwide.” The peptide-RI drug conjugates in the deal with Genentech are designed to use ...
- Source: drugdu
- 120
- September 30, 2023
Oxford Biodynamics launches prostate screening test

EpiSwitch is designed for men with prostate cancer risk in the UK and is 94% accurate Oxford BioDynamics – a company developing precision medicine tests – has announced that its EpiSwitch Prostate Screening (PSE) blood test will be available to UK patients. The existing PSA test is 55% accurate, and is considered an unreliable test by many doctors, including those in the NHS. The new PSE test has been designed to run alongside the standard PSA test, and combines the PSA score with five proprietary epigenetic biomarkers to predict – with 94% accuracy – the presence (or absence) of prostate cancer. The PSE test has emerged after nearly a decade’s long collaboration between OBD, Imperial College London, University of East Anglia, Imperial College NHS Trust and leading prostate cancer experts across the UK. The development was also part of the wider PROSTAGRAM screening pilot. Mathias Winkler, Consultant Urologist and Surgeon ...
- Source: drugdu
- 118
- September 29, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.